Koyfin Home > Directory > Health Care > Arcus Biosciences Inc

Arcus Biosciences Inc Price Chart RCUS

Historical daily share price chart and data for Arcus Biosciences Inc since 2018 adjusted for splits and dividends. The latest closing price for Arcus Biosciences Inc as of September 25, 2020 is $17.68.
  • In 2020 the stock opened at $10.10 and closed at $17.68 for a gain of 43% YTD.
  • In 2019 the stock opened at $10.55 and closed at $10.10 for a loss of -4%.
  • In 2018 the stock opened at $20.00 and closed at $10.77 for a loss of -86%.
View Chart On Koyfin

Arcus Biosciences Inc Summary

Stock Symbol: RCUS

Arcus Biosciences Inc Company Info

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company’s product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics (Cayman) Inc. The company was founded in 2015 and is based in Hayward, California.
Market Cap
Dividend Yield
0 %
Beta vs SPX
Short Interest
521.85 %
30D Volatility
Hedge Fund Held
0 %

Last 10 Days of RCUS Prices